Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

After a strong Q4 in 2009, net sales decreased 14% in Q1 to SEK 2,943 million (3,437). Mainly currency effects but also increased competition for Astelin and Optivar reduced sales by more than SEK 400 million, compared with the same period last year.

5 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

EpiCept Corporation today announced that it has earned a $2 million milestone payment from Meda AB, for the first commercial shipment of Ceplene® (histamine dihydrochloride) to a major country in the European Union, as defined in the agreement.

4 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

BioSante Pharmaceuticals, Inc. will present a BioSante cancer vaccine portfolio update at the BIO International Convention, which will take place May 3-6 in Chicago, Illinois.

30 Apr 2010

Study examines world-wide use of HSCT

An examination of the world-wide use of hematopoietic stem cell transplantation, which involves transplantation of blood stem cells derived from the bone marrow or blood, finds that there are significant differences in transplant rates between countries and continental regions by indication and donor type, and that HSCT is most frequently used in countries with higher gross national incomes and governmental health care expenditures, according to a study in the April 28 issue of JAMA.

28 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

High incidence of MDS among seniors, elderly at increased risk of premature death: Study

Myelodysplastic syndromes - a group of serious blood cancers - are nearly five times more common in seniors than previously thought, according to a new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center.

27 Apr 2010

OICR makes equity investments in three promising Ontario technologies

Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.

26 Apr 2010

Investment report on Array BioPharma

MicroStockProfit.com announces an investment report featuring Array BioPharma Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

21 Apr 2010

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that bafetinib (formerly known as INNO-406) has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of chronic myeloid leukemia (CML).

20 Apr 2010

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.

20 Apr 2010

EpiCept announces U.K. launch of Ceplene

EpiCept Corporation today announced that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission.

20 Apr 2010

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

The socioeconomic status of a country has long been considered a potentially significant factor in the availability of high-quality health-care interventions and even a determinant of long-term patient outcomes. A new study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation reports that in Europe, socioeconomic factors have a direct correlation to the rates and outcomes of stem cell transplantation for patients with acute myeloid leukemia (AML).

16 Apr 2010

Researchers identify new strategy for treating acute myeloid leukemia

Researchers have identified a self-feeding "vicious circle" of molecules that keeps acute leukemia cells alive and growing and that drives the disease forward.

15 Apr 2010

Harnessing body's own natural killer cells to battle cancer in children

Work underway at St. Jude Children's Research Hospital seeks to harnesses the body's own immune cells known as natural killer, or NK, cells to help children battle cancer. NK cells are the immune system's warriors. The cells circulate widely in the body, armed with proteins, called enzymes, capable of delivering a deadly one-two punch to viruses and cancer cells.

3 Apr 2010

Investment report on Sunesis Pharmaceuticals

StockPreacher.com announces an investment report featuring Sunesis Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

31 Mar 2010

New gateway may be lifesaver for patients with AML: Study

Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The findings from the Universit- de Montr-al, Maisonneuve-Rosemont Hospital and Universit- Laval may change the way doctors treat cancer patients.

26 Mar 2010

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.

23 Mar 2010

Acute Myeloid Leukemia News and Research

Further Reading

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

Study examines world-wide use of HSCT

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

High incidence of MDS among seniors, elderly at increased risk of premature death: Study

OICR makes equity investments in three promising Ontario technologies

Investment report on Array BioPharma

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

EpiCept announces U.K. launch of Ceplene

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

Researchers identify new strategy for treating acute myeloid leukemia

Harnessing body's own natural killer cells to battle cancer in children

Investment report on Sunesis Pharmaceuticals

New gateway may be lifesaver for patients with AML: Study

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Bridging the Gap between Academia and Industry: The Power of Collaboration in Life Sciences

Latest News